The FDA’s list of authorized AI-enabled medical devices surpassed 1,600 as of September 2026, according to the agency’s own tracking, with 181 new devices cleared in just the first six months of the year — a pace on track to exceed 2025’s full-year total of 335 clearances. The milestone reflects how thoroughly AI-enabled tools have moved from a niche regulatory category into a mainstream, high-volume segment of medical device approvals.
How Most of These Devices Actually Get Cleared
The overwhelming majority of AI-enabled device clearances — 96.2% according to FDA data — come through the agency’s 510(k) pathway, which allows a new device to reach market by demonstrating substantial equivalence to an already-cleared predicate device rather than requiring the more extensive clinical evidence typically needed for a De Novo classification or full premarket approval. That pathway’s dominance reflects how much of the AI medical device market now consists of incremental improvements to existing device categories — imaging analysis tools, diagnostic software updates — rather than entirely novel categories of device.
A List the FDA Says Isn’t Even Complete
Notably, the FDA itself has cautioned that its published list of AI-enabled devices is not a comprehensive resource covering every such device on the market, meaning the true number of AI-enabled tools in clinical use likely exceeds the 1,600 figure even before accounting for devices that may not meet the specific criteria for inclusion on the agency’s list. That caveat underscores how difficult it has become for regulators themselves to maintain a complete real-time picture of how extensively AI has penetrated the medical device landscape.
The UpDoc Clearance as a New Regulatory Frontier
Among the year’s most closely watched individual clearances was UpDoc, a patient-facing large language model cleared by the FDA in June 2026, representing what some observers have described as a new regulatory category for AI systems that interact directly with patients outside of traditional physician-mediated workflows. That clearance set a precedent regulators and industry will be watching closely as more companies seek authorization for AI tools designed to communicate directly with patients rather than simply assisting clinicians behind the scenes.
What’s Driving the Acceleration
The accelerating pace of clearances reflects both growing device-maker sophistication in navigating FDA’s AI-specific guidance and the agency’s own expanded frameworks for evaluating machine learning-based tools, including provisions for predetermined change control plans that allow certain AI models to update within pre-specified bounds without requiring a new clearance for every software iteration. That regulatory flexibility has made it commercially more viable for companies to bring AI-enabled devices to market, since it reduces the compliance burden associated with the continuous model updates that are a defining feature of machine learning systems.
Where the Growth Is Concentrated
Imaging-based diagnostic tools continue to represent the largest single category among authorized AI-enabled devices, spanning radiology, cardiology and ophthalmology applications where pattern recognition in medical images has proven to be one of the most mature and commercially successful applications of AI in clinical medicine to date. Newer categories, including AI tools for triage, risk prediction and now direct patient interaction following UpDoc’s clearance, represent the fastest-growing segments even though they still account for a smaller overall share of total clearances.
What Comes Next for Oversight
As the list of authorized devices continues growing at a record pace, health policy researchers and some lawmakers have called for more robust post-market surveillance to ensure AI-enabled devices continue performing as expected once deployed across diverse patient populations and clinical settings, beyond the controlled conditions under which they were originally cleared. How the FDA balances continued rapid authorization against strengthened post-market monitoring will likely shape the next phase of AI medical device regulation heading into 2027.
International Comparisons Add Context
Regulators in the European Union and United Kingdom have pursued somewhat different approaches to AI medical device oversight, with the EU’s broader AI Act creating additional compliance layers beyond traditional medical device regulation that US-based companies must separately navigate if they want to sell AI-enabled devices in European markets. That divergence in regulatory approach has led some device makers to prioritize FDA clearance first, given the comparatively faster and more established 510(k) pathway, before pursuing the more complex multi-layered approval process required to enter European markets with the same AI-enabled products.
What Patients and Clinicians Still Don’t Know
Despite the rapid pace of clearances, surveys of practicing clinicians have repeatedly found many remain unaware of exactly which AI tools embedded in their own hospital’s systems have received FDA authorization versus which are simply vendor-marketed features without any formal clearance, a gap in awareness that complicates informed clinical decision-making even as the underlying authorization numbers climb. Closing that awareness gap may ultimately require health systems themselves to do more to communicate clearance status to frontline clinical staff, rather than relying on the FDA’s public list alone to inform practice-level understanding.
Photo: fernandozhiminaicela / PIXABAY via Pixabay
